PMID- 24594499
OWN - NLM
STAT- MEDLINE
DCOM- 20141031
LR  - 20140305
IS  - 1878-6464 (Electronic)
IS  - 0957-4271 (Linking)
VI  - 24
IP  - 1
DP  - 2014
TI  - Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo 
      in the emergency department: A double blind, randomized clinical trial of 
      efficacy and safety.
PG  - 39-47
LID - 10.3233/VES-130506 [doi]
AB  - BACKGROUND: Vertigo imposes considerable health restrictions with significant 
      impact on the patient's quality of life. The most effective antivertigo agent is 
      undetermined thus far. OBJECTIVE: This study was performed to assess whether 
      promethazine has superior vertigo reduction compared with lorazepam in ED 
      patients. METHODS: In this randomized, double-blind, parallel group trial 184 
      patients were assigned (1:1 ratio) to receive either promethazine, 25 mg 
      intravenously, or lorazepam, 2 mg intravenously. Primary endpoint was mean change 
      in vertigo intensity at 2 hours measured using visual analog scale (VAS). 
      Secondary endpoints were mean change in nausea score, need for second dose of 
      study medications, and adverse events (AEs). RESULTS: Promethazine was associated 
      with significantly more reduction (46.5 mm) in vertigo than lorazepam (25.7 mm, 
      p< 0.001). Mean change in nausea score 2 hours after drug injection on the VAS 
      was 28.7 mm for promethazine and 22.8 for lorazepam (p=0.002). The most 
      frequently reported AEs were lethargy (14.1% in lorazepam group, 4.3% in 
      promethazine group, p=0.013) and drowsiness (10.8% for promethazine, 2.1% for 
      lorazepam, p=0.017). CONCLUSION: Our study demonstrated the evidence that 
      promethazine is superior to lorazepam in management of peripheral vertigo and 
      vertigo-related nausea in ED adults.
FAU - Amini, Afshin
AU  - Amini A
AD  - Department of Emergency Medicine, Imam Hossein Hospital, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Heidari, Kamran
AU  - Heidari K
AD  - Department of Emergency Medicine, Shohadaye-Haftom Tir Hospital, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Asadollahi, Shadi
AU  - Asadollahi S
AD  - School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Habibi, Tahereh
AU  - Habibi T
AD  - Department of Emergency Medicine, Imam Hossein Hospital, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Shahrami, Ali
AU  - Shahrami A
AD  - Department of Emergency Medicine, Imam Hossein Hospital, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Mansouri, Behnam
AU  - Mansouri B
AD  - Department of Neurology, Imam Hossein Hospital, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Kariman, Hamidreza
AU  - Kariman H
AD  - Department of Emergency Medicine, Imam Hossein Hospital, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Vestib Res
JT  - Journal of vestibular research : equilibrium & orientation
JID - 9104163
RN  - FF28EJQ494 (Promethazine)
RN  - O26FZP769L (Lorazepam)
SB  - IM
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Lorazepam/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nausea/*drug therapy
MH  - Promethazine/*therapeutic use
MH  - Vertigo
OTO - NOTNLM
OT  - Vertigo
OT  - clinical trial
OT  - lorazepam
OT  - nausea
OT  - promethazine
EDAT- 2014/03/07 06:00
MHDA- 2014/11/02 06:00
CRDT- 2014/03/06 06:00
PHST- 2014/03/06 06:00 [entrez]
PHST- 2014/03/07 06:00 [pubmed]
PHST- 2014/11/02 06:00 [medline]
AID - G002JH602628W5L5 [pii]
AID - 10.3233/VES-130506 [doi]
PST - ppublish
SO  - J Vestib Res. 2014;24(1):39-47. doi: 10.3233/VES-130506.